Stéphane Champiat, Associate Professor at MD Anderson Cancer Center, shared a post on LinkedIn:
“Grateful for the opportunity to present at SITC 2025 and engage with so many brilliant colleagues on the evolving role of radiomics in immunotherapy drug development!
Radiomics holds tremendous promise to transform how we develop immunotherapy.
It is more than a tool – it’s a catalyst. Now is the time for our community to scale radiomics broadly in clinical research and routine practice to accelerate innovation and deliver better outcomes for patients.”
More posts featuring Stéphane Champiat.